Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Bank of America upgraded Pharvaris from Neutral to Buy and set a $44 price target, citing a more attractive entry point after positive Phase 3 prophylaxis data; shares were up 2.74% at $31.52 at publication. The FDA is reviewing the on-demand deucrictibant NDA, with a decision expected April 23, 2027, while the company plans to file a prophylaxis NDA in the first half of 2027. Analyst Tazeen Ahmad estimates peak prophylaxis sales of $917 million assuming a 2028 launch, with oral drugs potentially capturing 30%-50% of the market; competition and limited switching from existing treatments temper the outlook.

Analysis

The key valuation gap is not whether the prophylaxis data look competitive, but whether an oral option can win new-patient starts without materially displacing established injectable and oral therapies. If switching is limited, the sales curve will depend on diagnosis, new-patient flow, payer access, and physician comfort—not simply the addressable market. On-demand commercialization could build prescriber and payer familiarity ahead of a prophylaxis filing, but it is also a separate competitive test against KalVista and may not translate into prophylaxis share.

The “clinical risk largely removed” framing is too strong: regulatory review, liver-safety interpretation, label language, and commercial uptake remain material. The two liver-enzyme cases may be manageable, but a monitoring requirement or restrictive label could weaken the convenience proposition and increase launch friction. Meanwhile, BioCryst may be more insulated than the headline’s competitive framing implies if switching is modest; its exposure is chiefly slower new-patient acquisition.

Near term, the analyst upgrade can support sentiment, but the major value inflection is distant: the on-demand FDA decision is scheduled for April 2027, with prophylaxis filing planned for 1H27 and launch economics modeled later. The main contrarian risk is treating projected oral penetration and peak sales as evidence of realized economics; verify prescribing intent, payer coverage, safety follow-up, and Pharvaris’s financing runway before underwriting those estimates.

Key Decisions for Investors

• PHVS: Consider only a staged, small long on weakness rather than chasing the upgrade. Add only if subsequent safety data and regulatory communications preserve a low-burden oral label and the planned prophylaxis filing remains on track; this is a multi-quarter catalyst, not a near-term FDA event.
• Do not short BCRX solely on this news. Limited switching could leave incumbent patients largely in place; reassess if launch data show PHVS taking new-patient starts or if BioCryst reports weakening Orladeyo demand or guidance.
• Track the April 2027 on-demand FDA decision, any liver-monitoring or label restrictions, payer coverage, and evidence of new-patient adoption. A safety-driven delay, restrictive label, or slippage in the prophylaxis filing would falsify the bullish adoption thesis.
• Before sizing PHVS against modeled peak sales, verify cash runway and expected funding needs, as well as launch pricing and access assumptions; the article does not establish these inputs.